Yang-Sui Liu1, Huan-Song Li1, Dun-Feng Qi1, Jun Zhang1, Xin-Chun Jiang1, Kui Shi1, Xiao-Jun Zhang1, Xin-Hui Zhang1. 1. Yang-Sui Liu, Huan-Song Li, Dun-Feng Qi, Jun Zhang, Xin-Chun Jiang, Kui Shi, Xiao-Jun Zhang, Xin-Hui Zhang, The Central Hospital of Xuzhou City, Xuzhou Hospital Affiliated to Medical College of Southeast University, Xuzhou 221009, Jiangsu Province, China.
Abstract
AIM: To investigate the effect of zinc protoporphyrin IX on the response of hepatoma cells to cisplatin and the possible mechanism involved. METHODS: Cytotoxicity was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Apoptosis was determined by a flow cytometric assay. Western blotting was used to measure protein expression. Heme oxygenase (HO)-1 activity was measured by determining the level of bilirubin generated in isolated microsomes. Reactive oxygen species (ROS) production was monitored by flow cytometry. Caspase-3 activity was measured with a colorimetric assay kit. Mice were inoculated with 1 × 10(7) tumor cells subcutaneously into the right flanks. All mice were sacrificed 6 wk after the first treatment and tumors were weighed and measured. RESULTS: Overexpression of HO-1 in HepG2 cell line was associated with increased chemoresistance to cis-diaminedichloroplatinum (cisplatin; CDDP) compared to other cell lines in vitro. Inhibition of HO-1 expression or activity by zinc protoporphyrin IX (ZnPP IX) markedly augmented CDDP-mediated cytotoxicity towards all liver cancer cell lines in vitro and in vivo. In contrast, induction of HO-1 with hemin increased resistance of tumor cells to CDDP-mediated cytotoxicity in vitro and in vivo. Furthermore, cells treated with ZnPP IX plus CDDP exhibited marked production of intracellular ROS and caspase-3 activity, which paralleled the incidence of cell apoptosis, whereas hemin decreased cellular ROS and caspase-3 activity induced by CDDP. CONCLUSION: ZnPP IX increases cellular sensitivity and susceptibility of liver cancer cell lines to CDDP and this may represent a mechanism of increasing ROS.
AIM: To investigate the effect of zinc protoporphyrin IX on the response of hepatoma cells to cisplatin and the possible mechanism involved. METHODS:Cytotoxicity was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Apoptosis was determined by a flow cytometric assay. Western blotting was used to measure protein expression. Heme oxygenase (HO)-1 activity was measured by determining the level of bilirubin generated in isolated microsomes. Reactive oxygen species (ROS) production was monitored by flow cytometry. Caspase-3 activity was measured with a colorimetric assay kit. Mice were inoculated with 1 × 10(7) tumor cells subcutaneously into the right flanks. All mice were sacrificed 6 wk after the first treatment and tumors were weighed and measured. RESULTS: Overexpression of HO-1 in HepG2 cell line was associated with increased chemoresistance to cis-diaminedichloroplatinum (cisplatin; CDDP) compared to other cell lines in vitro. Inhibition of HO-1 expression or activity by zinc protoporphyrin IX (ZnPP IX) markedly augmented CDDP-mediated cytotoxicity towards all liver cancer cell lines in vitro and in vivo. In contrast, induction of HO-1 with hemin increased resistance of tumor cells to CDDP-mediated cytotoxicity in vitro and in vivo. Furthermore, cells treated with ZnPP IX plus CDDP exhibited marked production of intracellular ROS and caspase-3 activity, which paralleled the incidence of cell apoptosis, whereas hemin decreased cellular ROS and caspase-3 activity induced by CDDP. CONCLUSION:ZnPP IX increases cellular sensitivity and susceptibility of liver cancer cell lines to CDDP and this may represent a mechanism of increasing ROS.
Entities:
Keywords:
Chemotherapy; Cisplatin; Heme oxygenase-1; Liver cancer cell lines; Zinc protoporphyrin IX
Authors: Yogesh K Vashist; Guentac Uzungolu; Asad Kutup; Florian Gebauer; Alexandra Koenig; Lena Deutsch; Oliver Zehler; Philipp Busch; Viacheslav Kalinin; Jakob R Izbicki; Emre F Yekebas Journal: J Surg Oncol Date: 2011-04-14 Impact factor: 3.454
Authors: Daniele Tibullo; Ignazio Barbagallo; Cesarina Giallongo; Piera La Cava; Nunziatina Parrinello; Luca Vanella; Fabio Stagno; Giuseppe A Palumbo; Giovanni Li Volti; Francesco Di Raimondo Journal: Curr Pharm Des Date: 2013 Impact factor: 3.116
Authors: Manuj Ahuja; Navneet Ammal Kaidery; Lichuan Yang; Noel Calingasan; Natalya Smirnova; Arsen Gaisin; Irina N Gaisina; Irina Gazaryan; Dmitry M Hushpulian; Ismail Kaddour-Djebbar; Wendy B Bollag; John C Morgan; Rajiv R Ratan; Anatoly A Starkov; M Flint Beal; Bobby Thomas Journal: J Neurosci Date: 2016-06-08 Impact factor: 6.167
Authors: Katherine Hu; Zhaowen Zhu; Meleah M Mathahs; Huy Tran; Jerry Bommer; Charles A Testa; Warren N Schmidt Journal: Drug Des Devel Ther Date: 2020-02-24 Impact factor: 4.162